Cancer is one of the most complex and adaptive diseases in modern medicine. Single-agent therapies often lead to partial responses, temporary remissions, or the emergence of drug resistance.
That’s why drug combination screening strategies, including in vitro drug combination screening, have become central to oncology drug development — enabling researchers to target tumors more precisely and durably.have become central to oncology drug development — enabling researchers to target tumors more precisely and durably.
In this article, we explore how drug combinations are reshaping cancer research by more effectively suppressing tumor growth and how advanced drug combination methods in oncology support more effective therapeutic discovery.
Why Oncology Demands Drug Combination Approaches
Tumors are heterogeneous in their molecular features, both within a single patient and across patient populations. Cancer cells evolve, evade immune detection, and adapt to targeted therapies. This complexity makes it difficult for monotherapies to achieve long-term success.
Combination therapies can:
-
Target multiple signaling pathways simultaneously
Tumors often activate redundant cell signaling pathways to escape therapeutic pressure. By inhibiting parallel or compensatory pathways (e.g., PI3K/AKT and MAPK), combination treatments can overcome adaptive resistance mechanisms, reduce tumor growth and induce deeper responses.
-
Disrupt tumor microenvironment (TME) support systems
The TME includes fibroblasts, endothelial cells, and immune suppressor cells that shield tumor cells from therapy. Targeting these components—such as angiogenesis or TGF-β signaling—enhances drug penetration and immune infiltration.
-
Engage both immune and cytotoxic mechanisms
Pairing agents that stimulate T cell activation (e.g., checkpoint inhibitors) with cytotoxic drugs or targeted inhibitors promotes a dual assault: one through immune-mediated killing, the other through apoptosis induction.
-
Reduce the likelihood of resistance
Tumor evolution is constrained when multiple survival strategies are simultaneously blocked. Rational combinations reduce the chance that a single mutation or bypass pathway will drive relapse.
For these reasons, drug combinations are now standard in many oncology protocols, from frontline treatment to relapse settings.
Focus Areas for Oncology Drug Combinations
In cancer research, several key areas have emerged where combination therapy shows promise:
-
Immune Checkpoint Inhibitors + Targeted Agents
Combining immune checkpoint blockade (e.g., anti-PD-1, anti-CTLA-4) with targeted agents (e.g., BRAF, EGFR, or VEGF inhibitors) can potentiate immune responses while simultaneously disrupting aberrant cell signaling involved in tumor growth. This approach is especially effective in immunologically “cold” tumors where checkpoint inhibitors alone show limited efficacy.
2. Chemotherapy + Molecular Therapies
Cytotoxic agents, including conventional chemotherapeutic agents, remain effective in reducing tumor volume and debulking tumors but can also prime the immune system by releasing neoantigens. When combined with DNA repair inhibitors (e.g., PARP inhibitors) or sensitizers, they improve selectivity and allow lower, less toxic doses.
3. TME Modulators
Strategies that alter the tumor microenvironment—such as IDO1 inhibitors, CSF1R inhibitors (targeting tumor-associated macrophages), or anti-angiogenic agents—can normalize vasculature, reduce hypoxia, and boost T cell infiltration, enhancing response to immunotherapies.
Each of these approaches addresses different aspects of tumor biology—such as immune modulation, metabolism, and cell signaling—and successful implementation requires tailored screening and model systems, including in vivo drug combination screening to ensure translational relevance.
Drug Screening Combinations in Oncology Models
To identify effective oncology drug combinations, researchers must simulate the tumor environment as closely as possible. At Kyinno, we support a variety of relevant models:
-
Cancer cell line panels including resistant and metastatic lines
Using diverse panels—including breast, lung, and endometrial cell lines—allows for screening across genetic backgrounds, tumor subtypes, molecular features and known resistance mutations—informing which combinations are most broadly effective or subtype-specific.
-
Co-culture systems with immune and stromal components
These models reflect tumor-immune-stroma interactions more realistically than monocultures and allow tracking of changes in tumor volume in response to immunomodulatory treatments, which can be further validated using western blot analysis to assess pathway-specific protein expression. They enable assessment of immunomodulatory agents and their ability to reshape TME dynamics.
-
3D spheroid and organoid models
These systems recreate spatial architecture, diffusion gradients, and cell–cell interactions found in vivo. Organoids derived from patient tumors also support personalized medicine and feed directly into the biomarker pipeline, enabling identification of predictive and prognostic markers in a physiologically relevant context.
-
High-throughput screening (HTS) platforms
HTS enables systematic testing of drug matrices across multiple doses and cell types, generating data on tumor volume reduction and other phenotypic outcomes. Integration with imaging or multiplexed readouts allows phenotypic profiling and rapid detection of synergistic or antagonistic effects.
These tools increase the predictive power of preclinical studies by providing early indications of tumor growth inhibition and reducing late-stage failures.
Preclinical Synergy Scoring in Oncology
Understanding synergy is key to prioritizing drug combinations for further development. In oncology, we apply multiple drug synergy scoring frameworks:
-
Bliss Independence
Assumes that drugs act independently. Synergy is observed when combined effects exceed the expected independent action. Ideal for evaluating agents with non-overlapping mechanisms.
-
Loewe Additivity
Suitable when agents have similar mechanisms or shared targets. It estimates synergy by assessing whether lower doses of each drug achieve the same effect when combined.
-
ZIP (Zero Interaction Potency) and HSA (Highest Single Agent)
ZIP provides a global synergy landscape, visualizing areas of maximal interaction, while HSA compares the combination effect to the most potent single agent—highlighting true enhancement.
End points include:
- Cell viability. Measures cytotoxicity or growth inhibition across monotherapy and combo conditions using assays such as MTT, CellTiter-Glo, or impedance-based systems.
- Apoptosis induction. Flow cytometry, caspase assays, western blot analysis of cleaved PARP or caspase-3, or Annexin V staining quantify programmed cell death—helping distinguish cytostatic from cytotoxic effects.
- Immune activation markers. In co-culture or immune-inclusive models, cytokine secretion (e.g., IFN-γ), T cell activation (e.g., CD69, CD25), or checkpoint expression (PD-L1) provide mechanistic insights into immuno-oncology combinations.
- Biomarker-driven mechanistic insights. Molecular profiling (e.g., RNA-seq, phospho-protein panels, western blot analysis) reveals cell signaling pathway activation or suppression, supporting rational selection of drug combination strategies and potential companion diagnostics.
Real-World Applications and Case Examples
Combination therapies have already delivered major oncology wins:
-
BRAF + MEK inhibitors in melanoma
These combinations improve progression-free and overall survival compared to monotherapy by reducing tumor volume and suppressing MAPK pathway reactivation, a common resistance route in BRAF-mutant tumors.
-
IO combinations (e.g., PD-1 + CTLA-4)
Dual checkpoint blockade has shown durable responses in non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma—by overcoming immune exhaustion and broadening T cell responses.
However, challenges remain:
-
Unexpected toxicity
Some oncology drug combinations—particularly those involving chemotherapeutic agents—amplify immune-related adverse events or overlapping toxicities (e.g., myelosuppression), limiting their clinical utility or requiring dose modification.
-
Antagonism from conflicting mechanisms
For example, combining an immunosuppressive corticosteroid with an immune checkpoint inhibitor may negate the therapeutic effect.
These risks reinforce the need for thorough preclinical validation before clinical translation.
Designing an Oncology Combo Study
Effective oncology combination studies require careful planning:
-
Select biologically complementary agents
Choose compounds that target distinct, but cooperative pathways (e.g., chemotherapeutic agents targeting the cell cycle + DNA repair; immune checkpoint + angiogenesis), increasing the chance of synergy.
-
Optimize dosing to reduce toxicity and maximize synergy
Implement dose–response matrices to identify the therapeutic window where efficacy is achieved without overlapping side effects.
-
Sequence treatments based on mechanism timing
Administering drugs in the correct order (e.g., priming with one agent before introducing the second) can influence therapeutic outcomes significantly, particularly in immuno-oncology.
Choosing the right in vitro or in vivo model is equally critical to ensure translational relevance, especially when assessing combination effects on tumor volume over time.
How Kyinno Supports Oncology Drug Combination Screening
At Kyinno, we specialize in custom oncology combination studies that reflect the complexity of real-world tumors.
Our platform offers:
-
Expertise in immuno-oncology and tumor resistance
We support screening across immune-enriched and drug-resistant models, helping identify combinations that address tumor escape and immune evasion.
-
AI-enhanced synergy prediction
Our machine learning models analyze historical datasets, biological markers, and cell signaling to prioritize compound pairs with the highest predicted synergistic potential—reducing unnecessary screening.
-
Cancer-focused assay customization
We tailor assay formats (2D/3D, co-culture, immune-inclusive) and endpoints (cytotoxicity, immunogenic cell death, biomarker expression, tumor growth suppression) to the client’s target indication and mechanism of interest.
-
Support for both discovery and IND-enabling phases
From exploratory screens to GLP-validated studies, we generate decision-grade data suitable for regulatory submission, partnering with clients through the full development lifecycle.
Whether you’re targeting solid tumors, hematologic cancers such as leukemias and lymphomas, or niche indications, we deliver the data you need to move forward with confidence.
Conclusion
Drug combination strategies are revolutionizing cancer therapy. With the right models, screening tools, and scientific support, researchers can uncover synergistic pairings that translate into real clinical impact.
→ Partner with Kyinno to accelerate your next drug combination screening. Book a consultation today.